Publication Name	World Journal of Gastroenterology
Manuscript ID	6686
Country	Germany

Received	2013-10-27 10:44
Peer-Review Started	2013-10-27 14:37
To Make the First Decision	2014-01-09 12:24
Return for Revision	2014-01-11 20:16
Revised	2014-01-26 18:58
Second Decision	2014-04-09 08:13
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief	2014-04-09 08:58
Articles in Press	2014-05-23 10:12
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2014-08-08 08:39
Publish the Manuscript Online	2014-08-20 18:38

ISSN	1007-9327 (print) and 2219-2840 (online)
Open Access
Copyright
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Oncology
Manuscript Type	Topic Highlights
Article Title	Translational research in pancreatic ductal adenocarcinoma: current evidence and future concepts
Manuscript Source	Invited Manuscript
All Author List	Stephan Kruger, Michael Haas, Steffen Ormanns, Sibylle Bächmann, Jens T Siveke, Thomas Kirchner, Volker Heinemann and Stefan Boeck
Funding Agency and Grant Number
Corresponding Author	Dr. Stefan Boeck, Department of Internal Medicine Ⅲ and Comprehensive Cancer Center, Klinikum Grosshadern, Ludwig-Maximilians-University of Munich, Marchioninistr. 15, D-81377 Munich, Germany. stefan.boeck@med.uni-muenchen.de
Key Words	Biomarker; Erlotinib; Gemcitabine; human equilibrative nucleoside transporter 1; KRAS; Nab-paclitaxel; p53; Pancreatic cancer; SMAD4; SPARC
Core Tip	Recent advances in the treatment of pancreatic ductal adenocarcinoma (PDA) have been made using the intensified chemotherapy regimen folinic acid, irinotecan and oxaliplatin, the recently FDA-approved nab-paclitaxel and the epidermal growth factor receptor-inhibitor erlotinib. Yet overall prognosis of PDA remains poor. To further improve outcome of PDA, innovative strategies are needed to identify patient subgroups that benefit most from specific regimens. This topic highlight focuses on potential biomarkers to identify patients that benefit from treatment with erlotinib (e.g. KRAS, AKT, ERK, p53), gemcitabine (hENT1, RRM1, dCK), nab-paclitaxel (SPARC) or angiogenesis inhibitors. Additional biomarkers of tumor biology (like SMAD4 and CXCR4) and future concepts of translational research in PDA are also discussed.
Publish Date	2014-08-20 18:38
Citation	Kruger S, Haas M, Ormanns S, Bächmann S, Siveke JT, Kirchner T, Heinemann V, Boeck S. Translational research in pancreatic ductal adenocarcinoma: current evidence and future concepts. World J Gastroenterol 2014; 20(31): 10769-10777
URL	http://www.wjgnet.com/1007-9327/full/v20/i31/10769.htm
DOI	http://dx.doi.org/10.3748/wjg.v20.i31.10769

Full Article (PDF)	WJG-20-10769.pdf
Full Article (Word)	WJG-20-10769.doc
Manuscript File	6686-Review.doc
Answering Reviewers	6686-Answering reviewers.pdf
Copyright License Agreement	6686-Copyright assignment.pdf
Peer-review Report	6686-Peer review(s).pdf
Scientific Editor Work List	6686-Scientific editor work list.doc